314 related articles for article (PubMed ID: 35596203)
1. Long-term impact of delayed follow-up due to COVID-19 lockdown on patients with neovascular age-related macular degeneration.
Szegedi S; Ebner C; Miháltz K; Wachter T; Vécsei-Marlovits PV
BMC Ophthalmol; 2022 May; 22(1):228. PubMed ID: 35596203
[TBL] [Abstract][Full Text] [Related]
2. Effects of the COVID-19 pandemic on neovascular age-related macular degeneration and response to delayed Anti-VEGF treatment.
Yeter DY; Dursun D; Bozali E; Ozec AV; Erdogan H
J Fr Ophtalmol; 2021 Mar; 44(3):299-306. PubMed ID: 33608176
[TBL] [Abstract][Full Text] [Related]
3. The importance of monitoring wet age-related macular degeneration patients during Coronavirus disease 19 pandemic: A retrospective study of assessment of functional and structural outcomes.
Tsiropoulos GN; Vallee R; Gallo Castro D; Ambresin A
J Fr Ophtalmol; 2022 Oct; 45(8):852-859. PubMed ID: 35908993
[TBL] [Abstract][Full Text] [Related]
4. The effect of COVID-19 pandemic restrictions on neovascular AMD patients treated with treat-and-extend protocol.
Sevik MO; Aykut A; Özkan G; Dericioğlu V; Şahin Ö
Int Ophthalmol; 2021 Sep; 41(9):2951-2961. PubMed ID: 33864577
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of a calculation model to estimate the impact of the COVID-19 pandemic lockdown on visual acuity in neovascular AMD.
Stattin M; Haas AM; Ahmed D; Graf A; Krepler K; Ansari-Shahrezaei S
Eur J Ophthalmol; 2022 Jul; 32(4):2312-2318. PubMed ID: 34726553
[TBL] [Abstract][Full Text] [Related]
6. Delaying anti-VEGF therapy during the COVID-19 pandemic: long-term impact on visual outcomes in patients with neovascular age-related macular degeneration.
Nassisi M; Pozzo Giuffrida F; Milella P; Ganci S; Aretti A; Mainetti C; Dell'Arti L; Mapelli C; Viola F
BMC Ophthalmol; 2023 Apr; 23(1):156. PubMed ID: 37069537
[TBL] [Abstract][Full Text] [Related]
7. Short-term outcomes of patients with neovascular exudative AMD: the effect of COVID-19 pandemic.
Borrelli E; Grosso D; Vella G; Sacconi R; Battista M; Querques L; Zucchiatti I; Prascina F; Bandello F; Querques G
Graefes Arch Clin Exp Ophthalmol; 2020 Dec; 258(12):2621-2628. PubMed ID: 33009973
[TBL] [Abstract][Full Text] [Related]
8. Predicting the immediate impact of national lockdown on neovascular age-related macular degeneration and associated visual morbidity: an INSIGHT Health Data Research Hub for Eye Health report.
Mollan SP; Fu DJ; Chuo CY; Gannon JG; Lee WH; Hopkins JJ; Hughes C; Denniston AK; Keane PA; Cantrell R
Br J Ophthalmol; 2023 Feb; 107(2):267-274. PubMed ID: 34518162
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of Eyes Lost to Follow-up with Neovascular Age-Related Macular Degeneration Receiving Intravitreal Anti-Vascular Endothelial Growth Factor.
Soares RR; Mellen P; Garrigan H; Obeid A; Wibbelsman TD; Borkar D; Ho AC; Hsu J
Ophthalmol Retina; 2020 Feb; 4(2):134-140. PubMed ID: 31540854
[TBL] [Abstract][Full Text] [Related]
10. Intravitreal Ranibizumab for neovascular Age-related macular degeneration in clinical practice: five-year treatment outcomes.
Zhu M; Chew JK; Broadhead GK; Luo K; Joachim N; Hong T; Syed A; Chang AA
Graefes Arch Clin Exp Ophthalmol; 2015 Aug; 253(8):1217-25. PubMed ID: 25205618
[TBL] [Abstract][Full Text] [Related]
11. The effect of a brief, unplanned treatment delay on neovascular age-related macular degeneration patients: a retrospective cohort study.
Zehden JA; Ghosh A; Soundararajan S; Tsujimoto THM; Jiang H; Lin FC; Blahnik T; Fleischman D; Zhang AY
Sci Rep; 2023 Feb; 13(1):3156. PubMed ID: 36823223
[TBL] [Abstract][Full Text] [Related]
12. IMPACT study: Impact of adherence to anti-VEGF intravitreal injections for macular disease during COVID 19-related confinement in France.
Hurand V; Ducloyer JB; Baudin F; Aho S; Weber M; Kodjikian L; Devin F; Gabrielle PH; Creuzot-Garcher C; Massin P;
Acta Ophthalmol; 2023 Feb; 101(1):91-99. PubMed ID: 35765939
[TBL] [Abstract][Full Text] [Related]
13. The Influence of COVID-19 on the Stability of Patients with Neovascular Age-Related Macular Degeneration with Different Treatment Regimens.
Jiang B; Gao L; Dong S; Hou Q; Sun M; Zhang J; Yu H; Zhang Z; Sun D
Adv Ther; 2022 Apr; 39(4):1568-1581. PubMed ID: 34817809
[TBL] [Abstract][Full Text] [Related]
14. The Impact of the COVID-19 Pandemic on the Quality of Care of Treatment-Naïve Patients with Neovascular Age-Related Macular Degeneration Receiving Intravitreal Aflibercept.
Angermann R; Franchi A; Frede K; Rettenwander J; Rettenwander T; Neyer J; Stattin M; Kralinger M; Zehetner C
Klin Monbl Augenheilkd; 2023 Nov; 240(11):1246-1254. PubMed ID: 35445380
[TBL] [Abstract][Full Text] [Related]
15. Management and Outcomes for Neovascular Age-Related Macular Degeneration: Analysis of United States Electronic Health Records.
Kiss S; Campbell J; Almony A; Shih V; Serbin M; LaPrise A; Wykoff CC
Ophthalmology; 2020 Sep; 127(9):1179-1188. PubMed ID: 32345477
[TBL] [Abstract][Full Text] [Related]
16. Long-term Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration: The LATAR Study: Report 1: Ten-Year, Real-World Outcomes.
Spooner K; Fraser-Bell S; Hong T; Phan L; Wong JG; Chang A
Ophthalmol Retina; 2021 Jun; 5(6):511-518. PubMed ID: 33007523
[TBL] [Abstract][Full Text] [Related]
17. Real-life management of neovascular age-related macular degeneration (nAMD) in France: a nationwide observational study using retrospective claims data.
Korobelnik JF; Delcourt C; Creuzot-Garcher C; Melaine A; Chassetuillier J; Lejeune A; Bénard S; Dupont-Benjamin L
J Med Econ; 2021; 24(1):1087-1097. PubMed ID: 34420480
[TBL] [Abstract][Full Text] [Related]
18. NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH ADVANCED VISUAL LOSS TREATED WITH ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY: Clinical Outcome and Prognostic Indicators.
Vogel RN; Davis DB; Kimura BH; Rathinavelu S; Graves GS; Szabo A; Han DP
Retina; 2017 Feb; 37(2):257-264. PubMed ID: 27429385
[TBL] [Abstract][Full Text] [Related]
19. Visual acuity outcomes of anti-VEGF treatment for neovascular age-related macular degeneration in clinical trials.
Yamashiro K; Oishi A; Hata M; Takahashi A; Tsujikawa A
Jpn J Ophthalmol; 2021 Nov; 65(6):741-760. PubMed ID: 34491474
[TBL] [Abstract][Full Text] [Related]
20. Real-World Effectiveness and Real-World Cost-Effectiveness of Intravitreal Aflibercept and Intravitreal Ranibizumab in Neovascular Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Real-World Studies.
Carrasco J; Pietsch GA; Nicolas MP; Koerber C; Bennison C; Yoon J
Adv Ther; 2020 Jan; 37(1):300-315. PubMed ID: 31728825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
